Impax Asset Management Group plc Takes $7.57 Million Position in Merus (NASDAQ:MRUS)

Impax Asset Management Group plc purchased a new stake in shares of Merus (NASDAQ:MRUS) in the fourth quarter, HoldingsChannel.com reports. The fund purchased 180,000 shares of the biotechnology company’s stock, valued at approximately $7,569,000.

Other institutional investors have also recently modified their holdings of the company. Avior Wealth Management LLC acquired a new position in shares of Merus during the 4th quarter worth approximately $76,000. US Bancorp DE acquired a new position in shares of Merus during the 3rd quarter worth approximately $103,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Merus by 24.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,467 shares of the biotechnology company’s stock worth $118,000 after purchasing an additional 489 shares during the last quarter. MML Investors Services LLC acquired a new position in shares of Merus during the 3rd quarter worth approximately $206,000. Finally, Gordian Capital Singapore Pte Ltd grew its stake in Merus by 10.4% in the 3rd quarter. Gordian Capital Singapore Pte Ltd now owns 5,000 shares of the biotechnology company’s stock worth $250,000 after acquiring an additional 470 shares during the period. 96.14% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have commented on MRUS shares. Piper Sandler started coverage on shares of Merus in a research note on Thursday, February 13th. They issued an “overweight” rating and a $84.00 target price for the company. Guggenheim reaffirmed a “buy” rating on shares of Merus in a research note on Wednesday, February 12th. The Goldman Sachs Group started coverage on shares of Merus in a research note on Thursday, November 21st. They issued a “buy” rating and a $73.00 target price for the company. Wells Fargo & Company started coverage on shares of Merus in a research note on Friday, February 7th. They issued an “overweight” rating and a $91.00 target price for the company. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $85.00 target price on shares of Merus in a research note on Monday, December 9th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $85.92.

Merus Price Performance

Shares of MRUS stock opened at $46.75 on Tuesday. Merus has a 12 month low of $37.77 and a 12 month high of $61.61. The firm has a market capitalization of $3.20 billion, a P/E ratio of -11.84 and a beta of 1.11. The company’s fifty day moving average price is $41.80 and its two-hundred day moving average price is $46.89.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.